Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 70/100

Failure Rate

14.3%

1 terminated/withdrawn out of 7 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

14%

1 trials in Phase 3/4

Results Transparency

0 of 0 completed trials have results

Key Signals

3 recruiting

Enrollment Performance

Analytics

Phase 1

6(85.7%)

Phase 3

1(14.3%)

7Total

Phase 1(6)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT07150806Phase 1Suspended

RYZ101 for the Treatment of Progressive or Recurrent Intracranial Meningioma

Role: collaborator

NCT05595460Phase 1Active Not Recruiting

Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC

Role: lead

NCT06726161Phase 1Recruiting

Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ (Glypican-3) Unresectable HCC

Role: lead

NCT07165132Phase 1Recruiting

Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.

Role: lead

NCT05477576Phase 3Recruiting

Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy

Role: lead

NCT06590857Phase 1Active Not Recruiting

Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.

Role: lead

NCT06411301Phase 1Withdrawn

A Phase I Study to Assess the Tolerability of 225Ac-DOTATATE in Patients With Refractory and Relapsing Multiple Myeloma Expressing Somatostatin Receptors

Role: collaborator

All 7 trials loaded